[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Takeda Pharmaceutical Ltd ADR (TAK)

Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 50,792,032
  • Shares Outstanding, K 3,182,458
  • Annual Sales, $ 29,738 M
  • Annual Income, $ 1,266 M
  • EBIT $ 2,182 M
  • EBITDA $ 11,639 M
  • 60-Month Beta -0.06
  • Price/Sales 1.81
  • Price/Cash Flow 5.20
  • Price/Book 1.00

Options Overview Details

View History
  • Implied Volatility 27.72% (-6.05%)
  • Historical Volatility 22.59%
  • IV Percentile 34%
  • IV Rank 18.64%
  • IV High 72.40% on 10/29/25
  • IV Low 17.48% on 06/17/25
  • Expected Move (DTE 17) 1.79 (11.75%)
  • Put/Call Vol Ratio 0.29
  • Today's Volume 170
  • Volume Avg (30-Day) 639
  • Put/Call OI Ratio 2.25
  • Today's Open Interest 11,228
  • Open Int (30-Day) 10,017
  • Expected Range 13.41 to 16.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.39
  • Number of Estimates 1
  • High Estimate $0.39
  • Low Estimate $0.39
  • Prior Year $0.52
  • Growth Rate Est. (year over year) -25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.08 +0.73%
on 06/01/26
16.92 -10.22%
on 05/07/26
-1.43 (-8.60%)
since 05/01/26
3-Month
15.08 +0.73%
on 06/01/26
18.90 -19.61%
on 04/01/26
-3.56 (-18.99%)
since 02/27/26
52-Week
12.99 +16.94%
on 10/30/25
18.90 -19.61%
on 04/01/26
+0.16 (+1.06%)
since 05/30/25

Most Recent Stories

More News
Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda

Plaintiffs’ attorneys celebrate massive antitrust win against rising pharmaceutical costs

TAK : 15.19 (-4.82%)
Takeda Pharmaceutical Q4 Earnings Call Highlights

Takeda Pharmaceutical (NYSE:TAK) reported fiscal 2025 results that management described as solid despite pressure from generic competition to VYVANSE, while outlining a transition plan built around three...

TAK : 15.19 (-4.82%)
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results

FY2025 Pipeline Successes Set the Stage for Pivotal Product Launches Achieved Latest FY2025 Management Guidance ...

TAK : 15.19 (-4.82%)
Can Takeda's Pipeline Progress Finally Translate Into Guidance the Street Wants to Hear?

Barchart Research What to Expect from TAK Earnings TAK Generated May 12, 2026 Current Price $16.42 EPS Estimate $$0.21 Consensus Rating Moderate Buy Average Move 3.15% Can Takeda's Pipeline Progress Finally...

TAK : 15.19 (-4.82%)
Home Sales, Inflation to be Released This Week

Monday U.S. Economic Lookahead Existing home sales (April) Featured Earnings ...

SONY : 22.57 (+4.64%)
AMAT : 458.17 (+1.80%)
VIV : 13.19 (+0.38%)
CSCO : 121.33 (+0.76%)
CEG : 265.70 (-7.66%)
NU : 12.99 (-1.07%)
FLO : 7.66 (+0.26%)
SPG : 202.70 (-1.08%)
BN : 45.32 (-0.59%)
SE : 95.25 (+5.21%)
RBC : 566.14 (-1.02%)
USAS : 6.25 (+1.46%)
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)

Investigational TAK-881 was comparable to established HYQVIA while also demonstrating reduced infusion volume and duration for PID patients

TAK : 15.19 (-4.82%)
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate...

TAK : 15.19 (-4.82%)
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera

Rusfertide Demonstrated Significant Improvements in Hematocrit Control, Phlebotomy Reduction and Patient Reported Outcomes for Patients with Polycythemia Vera in a Pivotal Study ...

PTGX : 94.92 (-4.66%)
TAK : 15.19 (-4.82%)
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity

EQNX::TICKER_START (NASDAQ:HELP),(CBOE:HELP),(NYSE:TAK),(NASDAQ:CMPS),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END

HELP : 4.69 (+3.08%)
CMPS : 14.19 (+8.65%)
PFE : 25.63 (-2.10%)
TAK : 15.19 (-4.82%)
BMY : 54.95 (-3.90%)
Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis

Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conventional treatment options or tumor necrosis factor...

TAK : 15.19 (-4.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

Relative Strength just crossed below 30%. The market has entered oversold territory.

See More Share

Business Summary

Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide...

See More

Key Turning Points

3rd Resistance Point 15.85
2nd Resistance Point 15.68
1st Resistance Point 15.43
Last Price 15.19
1st Support Level 15.01
2nd Support Level 14.84
3rd Support Level 14.59

See More

52-Week High 18.90
Fibonacci 61.8% 16.64
Fibonacci 50% 15.94
Fibonacci 38.2% 15.25
Last Price 15.19
52-Week Low 12.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.